Web Exclusives

The importance of the UK building a domestic pharmaceutical and vaccine manufacturing sector, both in the context of COVID-19 and exiting the EU

Neurodivergent individuals are systematically overlooked in recruitment processes but are a talent pool that could be highly valuable to the pharma sector, says Marita Hazeldene

Victoria Langdon says it’s time for big pharma to step up…or risk losing out to big tech

Accenture’s Brad Michel considers how life sciences companies can begin to re-open as we tentatively move to easing lockdown restrictions

GSK’s Andrew Barraclough considers why brands should make design core to their strategy

While the effort to treat and manage COVID-19 is underway, here’s how companies can also stay focused on developing treatments for all patients

What can we expect to see for real world evidence in 2020 and beyond?

More than half of women take home less pay after a cancer diagnosis. It is time to talk about the ‘ripple effect’ of a cancer diagnosis, says Pfizer’s Dr Olivia Ashman

PharmaTimes talks to Biogen’s Natalie Ghafoor about her role and views on the rare disease landscape

Rare Disease Day is a fixture in the calendar not only for affected patients and families, and patient advocacy organisations, but also the myriad of other stakeholders that make up the rare disease ecosystem

Natalie Douglas looks at the ongoing needs and challenges for rare disease patients and their care moving forward

How the Internet of Medical Things (IoMT) can streamline clinical ops – and why it’s worth the investment

Giving cancer research the best chance of success